Nitric Oxide Modulation in Renal Health and Disease
Summary
Nitric oxide (NO) is a pivotal gaseous mediator in the renal vasculature and tubulointerstitium, finely regulating blood flow, glomerular filtration and tubular reabsorption. Synthesised chiefly by endothelial nitric oxide synthase (eNOS) in the renal microcirculation, NO maintains glomerular hemodynamics and inhibits adhesion of inflammatory cells to the endothelium. In pathological states such as hypertension, diabetic nephropathy and chronic kidney disease (CKD), bioavailability of NO is diminished by oxidative stress, asymmetric dimethylarginine accumulation and dysregulated NOS expression. This deficit fosters vasoconstriction, inflammation and fibrogenesis, accelerating progression to end-stage renal failure. Conversely, inducible NOS (iNOS) overactivity in acute injury can generate cytotoxic concentrations of NO and peroxynitrite. Therapeutic strategies that restore eNOS activity, scavenge reactive oxygen species or modulate endogenous NOS inhibitors have shown promise in preclinical models and early clinical studies. Advances in targeted delivery of NO donors and small-molecule activators of NOS are now converging with biomaterial-based approaches to achieve organ-selective restoration of NO signalling, with the aim of preserving renal structure and function across a spectrum of acute and chronic insults.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Nitric Oxide Modulation in Renal Health and Disease publication trend
The graph below shows the total number of articles in nitric oxide modulation in renal health and disease across all publications each year (not limited to Nature Index journals).
Technical terms
Endothelial nitric oxide synthase (eNOS): enzyme in vascular endothelium that produces NO to regulate vessel tone and glomerular filtration.
Inducible nitric oxide synthase (iNOS): isoform of NOS upregulated in inflammation, capable of generating high NO levels that may be cytotoxic.
Asymmetric dimethylarginine (ADMA): endogenous inhibitor of NOS that accumulates in renal dysfunction and impairs NO production.
Dimethylarginine dimethylaminohydrolase (DDAH): enzyme that degrades ADMA, thereby enhancing NO availability.
NO donor: compound or formulation that releases nitric oxide in vivo to supplement endogenous production.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.